Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
CuraTeQ Biologics is on track for filing a second oncology biosimilar
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
This is Enzene Biosciences third biosimilar to be approved
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
